Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults...(lung diseases-- emphysema and chronic br...),Health

Date:10/29/2008

lung diseases -- emphysema and chronic bronchitis -- which result in decreased quality of life, chronic airway inflammation and progressive loss of lung function, making it difficult to breathe normally.(8) Common symptoms include shortness of breath, chronic cough, wheezing and excess mucus.(8) In patients with severe to very severe COPD, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the addition of inhaled corticosteroids (ICS) to long-acting beta2-agonists (LABA), in addition to other treatment options, to reduce exacerbations and improve lung function and health status.(9) COPD is a progressive disease, which means people with COPD can expect lung function to worsen over time.(9) When symptoms are severe, it can be difficult for a person to perform simple, daily tasks.(8) As the disease progresses, people with COPD may eventually require supplemental oxygen and may ultimately have to rely on mechanical ventilatory assistance.(10)

About SYMBICORT

SYMBICORT is a combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older.(6) SYMBICORT is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled short-acting beta2- agonists.(6) Administered twice daily,(6) SYMBICORT is a combination of two proven asthma medications-budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA).(6) SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.(6)

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly w
'/>"/>

SOURCE AstraZeneca Copyright©2008 PR Newswire. All rights reserved

4 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
5. Recruitment Completed in Ofatumumab NHL Pivotal Study
6. Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs
7. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
8. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
9. 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
10. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
11. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial